TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06794541: Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Intravenous Eravacycline in Pediatric Patients From 8 Years to Less Than 18 Years of Age With Complicated Intra-abdominal Infections (cIAI)

Sponsor: Tetraphase Pharmaceuticals, Inc · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 35 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$5,321,400

Rescue Site Savings

+$3,498,600

Unlock Full NCT06794541 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06794541 Rescue Dossier →